Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: ADN012
MIFTS: 43

Adenocarcinoma in Situ

Categories: Cancer diseases, Endocrine diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Adenocarcinoma in Situ

About this section

MalaCards integrated aliases for Adenocarcinoma in Situ:

Name: Adenocarcinoma in Situ 12 44 15 71

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Endocrine diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:4943
MeSH 44 D065311
NCIt 50 C4123
SNOMED-CT 67 51642000
UMLS 71 C0334276
Sources

Summaries for Adenocarcinoma in Situ

About this section
Disease Ontology : 12 An in situ carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary : Adenocarcinoma in Situ is related to early invasive cervical adenocarcinoma and adenocarcinoma. An important gene associated with Adenocarcinoma in Situ is KRAS (KRAS Proto-Oncogene, GTPase), and among its related pathways/superpathways are Mitotic G1-G1/S phases and Cell cycle. The drugs Vaccines and Immunologic Factors have been mentioned in the context of this disorder. Affiliated tissues include cervix, lung and prostate, and related phenotypes are Reduced mammosphere formation and cellular

Sources

Related Diseases for Adenocarcinoma in Situ

About this section

Diseases in the Adenocarcinoma family:

Adenocarcinoma in Situ

Diseases related to Adenocarcinoma in Situ via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 356)
# Related Disease Score Top Affiliating Genes
1 early invasive cervical adenocarcinoma 32.0 INSM1 CDKN2A
2 adenocarcinoma 31.0 KRT7 KRAS CEACAM5 CDX2 CDKN2A CDKN1A
3 neuroendocrine carcinoma 30.6 KRT7 KRT20 CEACAM5
4 cervical adenocarcinoma 30.6 KRT7 KRT20 KRAS CEACAM5 CDX2 CDKN2A
5 appendix adenocarcinoma 30.5 KRT7 KRT20 KRAS CEACAM5 CDX2
6 adenosquamous carcinoma 30.5 KRT7 KRAS CEACAM5
7 suppressor of tumorigenicity 3 30.4 CDKN2A CDKN1A CA9
8 endometrial adenocarcinoma 30.4 KRT7 KRAS CDKN2A
9 anal gland adenocarcinoma 30.4 KRT7 CDX2
10 adenoma 30.4 KRT7 KRT20 KRAS CDX2 CDKN2A
11 urachal adenocarcinoma 30.4 KRAS CEACAM5
12 mucinous adenocarcinoma 30.3 KRT7 KRT20 KRAS CEACAM5 CDX2 CDKN2A
13 eccrine papillary adenoma 30.2 KRT7 KRAS CEACAM5
14 mature teratoma 30.2 KRT7 KRAS CEACAM5
15 glandular cystitis 30.2 KRT7 KRT20 CDX2
16 cystadenoma 30.2 KRT7 KRT20 CEACAM5
17 duodenum adenocarcinoma 30.1 KRT7 KRAS CEACAM5 CDX2
18 intrahepatic cholangiocarcinoma 30.0 KRT7 KRT20 KRAS CDX2
19 cystic teratoma 29.9 KRT7 KRT20 KRAS CDX2 CDKN2A
20 villous adenoma 29.9 KRT7 KRT20 KRAS CEACAM5 CDX2
21 pseudomyxoma peritonei 29.9 KRT7 KRT20 KRAS CEACAM5 CDX2
22 bronchiolo-alveolar adenocarcinoma 29.9 U2AF1 KRT7 KRT20 KRAS CEACAM5 CDX2
23 cholangiocarcinoma 29.8 KRT7 KRT20 KRAS CEACAM5 CDX2
24 benign teratoma 29.8 PAX8 KRT7 KRT20 CEACAM5 CDX2
25 peritoneum cancer 29.7 WT1 PAX8 KRT7 CEACAM5 CDKN2A
26 teratoma 29.7 KRT7 KRT20 KRAS CEACAM5 CDX2 CDKN2A
27 colorectal adenocarcinoma 29.7 KRT7 KRT20 KRAS CEACAM5 CDX2 CDKN2A
28 papillary carcinoma 29.6 PAX8 KRT7 KRT20
29 lung cancer susceptibility 3 29.6 U2AF1 KRT7 KRT20 KRAS CEACAM5 CDX2
30 papilloma 29.5 KRT7 KRT20 KRAS CDKN2A CDKN1A
31 barrett esophagus 29.5 MCM2 KRT7 KRT20 CDX2 CDKN2A CDKN1A
32 transitional cell carcinoma 29.5 KRT7 KRT20 CDKN2A CDKN1A CA9
33 colon adenocarcinoma 29.4 KRT20 KRAS CEACAM5 CDKN1A
34 endometrial cancer 29.3 WT1 PAX8 KRT7 KRT20 KRAS CEACAM5
35 endocervical adenocarcinoma 29.3 U2AF1 PAX8 PAX2 KRT7 KRT20 CEACAM5
36 ovarian mucinous neoplasm 29.0 U2AF1 PAX8 KRT7 KRT20 KRAS CEACAM5
37 pulmonary adenocarcinoma in situ 11.4
38 cervix uteri carcinoma in situ 10.5
39 cervical intraepithelial neoplasia 10.5
40 in situ carcinoma 10.5
41 trachea carcinoma in situ 10.4 KRAS CDKN2A
42 ovary neuroendocrine neoplasm 10.4 KRT7 CDX2
43 cervical basaloid squamous cell carcinoma 10.4 KRT7 CDKN2A
44 signet ring basal cell carcinoma 10.4 KRAS CEACAM5
45 gastric signet ring cell adenocarcinoma 10.4 KRT7 CDX2
46 immature teratoma of ovary 10.4 KRAS CEACAM5
47 leukoplakia of penis 10.4 KRT7 CEACAM5
48 anus adenocarcinoma 10.4 KRT7 CDX2
49 pancreatic cystadenocarcinoma 10.4 KRAS CEACAM5
50 inverted transitional papilloma 10.4 KRT7 CDKN2A

Graphical network of the top 20 diseases related to Adenocarcinoma in Situ:



Diseases related to Adenocarcinoma in Situ
Sources

Symptoms & Phenotypes for Adenocarcinoma in Situ

About this section

GenomeRNAi Phenotypes related to Adenocarcinoma in Situ according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.23 CA9 CLDN1 KRAS KRT7 MCM2 MCM7

MGI Mouse Phenotypes related to Adenocarcinoma in Situ:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.15 CDKN1A CDKN2A CDX2 INSM1 KRAS KRT7
2 embryo MP:0005380 10 CDKN1A CDKN2A CDX2 CLDN1 KRAS MCM2
3 digestive/alimentary MP:0005381 9.92 CA9 CDKN1A CDKN2A CDX2 INSM1 KRAS
4 endocrine/exocrine gland MP:0005379 9.9 CA9 CDKN1A CDKN2A CDX2 INSM1 KRAS
5 mortality/aging MP:0010768 9.8 CA9 CDKN1A CDKN2A CDX2 CLDN1 INSM1
6 no phenotypic analysis MP:0003012 9.17 CDKN1A CDKN2A INSM1 KRAS PAX8 SOX17
Sources

Drugs & Therapeutics for Adenocarcinoma in Situ

About this section

Drugs for Adenocarcinoma in Situ (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 17)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Vaccines Phase 3
2 Immunologic Factors Phase 3
3
Sargramostim Approved, Investigational Phase 1, Phase 2 123774-72-1, 83869-56-1
4
Testosterone Approved, Investigational Phase 1, Phase 2 58-22-0 6013
5
Cyclophosphamide Approved, Investigational Phase 1, Phase 2 50-18-0, 6055-19-2 2907
6
Metformin Approved Phase 2 657-24-9 14219 4091
7 Molgramostim Investigational Phase 1, Phase 2 99283-10-0
8 Immunosuppressive Agents Phase 1, Phase 2
9 Hormones Phase 1, Phase 2
10 Antirheumatic Agents Phase 1, Phase 2
11 Alkylating Agents Phase 1, Phase 2
12 Androgens Phase 1, Phase 2
13 Hypoglycemic Agents Phase 2
14
Proflavine Approved 92-62-6 7099
15 Anti-Infective Agents
16 Pharmaceutical Solutions
17 Anti-Infective Agents, Local

Interventional clinical trials:

(show all 14)
# Name Status NCT ID Phase Drugs
1 A Phase IV Open-Label, Descriptive Study to Evaluate the Safety and Effectiveness on the Incidence of HPV 6, 11, 16 and 18 Related CIN 2/3 or Worse of the Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in 16- to 26-Year-Old Japanese Women Completed NCT01544478 Phase 4
2 A Phase III Open-label Safety and Immunogenicity Study of GARDASILâ„¢9 Administered to 9- to 26-Year-Old Females and Males in Vietnam Completed NCT03546842 Phase 3
3 A Double-Blind, Controlled, Randomized, Phase III Study of the Efficacy of an HPV16/18 VLP Vaccine in the Prevention of Advanced Cervical Intraepithelial Neoplasia (CIN2, CIN3, Adenocarcinoma In Situ [AIS] and Invasive Cervical Cancer) Associated With HPV 16 or HPV 18 Cervical Infection in Healthy Young Adult Women in Costa Rica. Completed NCT00128661 Phase 3
4 A Phase 3 Open-Label Clinical Trial to Study the Immunogenicity, Safety and Tolerability of Recombinant Human Papillomavirus Quadrivalent (Types 6, 11, 16, 18) Vaccine (V501) in Chinese Girls Aged 9-19 Years and Young Women Aged 20-26 Years Active, not recruiting NCT03493542 Phase 3
5 Comparison of Video-assisted Thoracoscopic Segmentectomy Versus Lobectomy for Lung Adenocarcinoma in Situ and With Microinvasion Not yet recruiting NCT02011997 Phase 3
6 A Neoadjuvant Immunologic Study of Androgen Deprivation Therapy Combined With a Granulocytemacrophage-colony Stimulating Factor F-secreting Allogeneic Prostate Cancer Vaccine and Low-dose Cyclophosphamide in Men With High-risk Localized Prostate Cancer Undergoing Radical Prostatectomy Completed NCT01696877 Phase 1, Phase 2 degarelix acetate;Cyclophosphamide;GVAX
7 Metformin With Neoadjuvant Chemoradiation to Improve Pathologic Responses in Rectal Cancer: An Internal Pilot Study Completed NCT03053544 Phase 2 Metformin
8 Prevalence of Anal Dysplasia and Anal Cancer in Women With Cervical, Vaginal and Vulvar Dysplasia and Cancer Recruiting NCT02140021
9 HSIL/ACIS/Early Cervical Cancer: What Are The Current Causative HPV Subtypes in the Era of HPV Vaccination? Recruiting NCT02937155
10 CT-based Radiomic Algorithm for Assisting Surgery Decision and Predicting Immunotherapy Response of NSCLC Recruiting NCT04452058
11 A Clinical Test for the Treatment of Multifocal Lung Cancers Using Genome Active, not recruiting NCT02705404
12 A Clinical Pathway for the Treatment of Multifocal Lung Adenocarcinoma Using Genome Sequencing Active, not recruiting NCT01946100
13 Use of High-Resolution Microendoscopy (HRME) in Patients With Adenocarcinoma In-Situ (AIS) of the Cervix Active, not recruiting NCT02206048 Proflavine
14 Pilot Study of the Hand-held In Vivo Confocal Microscopy Probe for Detection of Cervical Intraepithelial Neoplasia Suspended NCT02574442

Search NIH Clinical Center for Adenocarcinoma in Situ

Cochrane evidence based reviews: adenocarcinoma in situ

Sources

Genetic Tests for Adenocarcinoma in Situ

About this section
Sources

Anatomical Context for Adenocarcinoma in Situ

About this section

MalaCards organs/tissues related to Adenocarcinoma in Situ:

40
Cervix, Lung, Prostate, Lymph Node, Colon, Pancreas, Thyroid
Sources

Publications for Adenocarcinoma in Situ

About this section

Articles related to Adenocarcinoma in Situ:

(show top 50) (show all 1347)
# Title Authors PMID Year
1
The Silva Pattern-based Classification for HPV-associated Invasive Endocervical Adenocarcinoma and the Distinction Between In Situ and Invasive Adenocarcinoma: Relevant Issues and Recommendations From the International Society of Gynecological Pathologists. 61
33570863 2021
2
Two Asian families with gastric adenocarcinoma and proximal polyposis of the stomach successfully treated via laparoscopic total gastrectomy. 61
33242120 2021
3
Is 99m Tc bone scintigraphy necessary in the preoperative workup for patients with cT1N0 subsolid lung cancer? A prospective multicenter cohort study. 61
33210466 2021
4
A radiomics study to predict invasive pulmonary adenocarcinoma appearing as pure ground-glass nodules. 61
33187676 2021
5
Can computed tomography differentiate adenocarcinoma in situ from minimally invasive adenocarcinoma? 61
33599059 2021
6
Follow-up Findings in Postconservative Treatment Surveillance for Women With Cervical Adenocarcinoma In Situ. 61
33284146 2021
7
Gastric-type cervical adenocarcinoma with squamous differentiation: buried in adenosquamous carcinomas? 61
33404855 2021
8
[Surgical Treatment and Outcomes for Synchronous Multiple Lung Cancer]. 61
33550313 2021
9
CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinoma. 61
33416944 2021
10
Radiological imaging and pathological findings of small lung adenocarcinoma: a narrative review. 61
33569217 2021
11
The role of Pap smear in the diagnostics of endocervical adenocarcinoma. 61
33445208 2021
12
Cytomorphologic Features of Gastric-Type Endocervical Adenocarcinoma in Liquid-Based Preparations. 61
33152741 2021
13
Evolution of DNA methylome from precancerous lesions to invasive lung adenocarcinomas. 61
33514726 2021
14
Predictors of upstage and treatment strategies for stage IA lung cancers after sublobar resection for adenocarcinoma in situ and minimally invasive adenocarcinoma. 61
33569291 2021
15
Incidental Gallbladder Cancer: Routine versus Selective Histological Examination After Cholecystectomy. 61
33542953 2021
16
[Anatomical partial lobectomy for the treatment of 3 336 cases of patients with lung nodule]. 61
33472327 2021
17
Clinical performance of the aptima HPV assay in 4196 women with positive high-risk HPV and ASC-US cytology: A large women hospital experience. 61
32857920 2021
18
Excisional treatment comparison for in situ endocervical adenocarcinoma (EXCISE): A phase 2 pilot randomized controlled trial to compare histopathological margin status, specimen size and fragmentation after loop electrosurgical excision procedure and cold knife cone biopsy. 61
33032824 2020
19
Surgery for pre- and minimally invasive lung adenocarcinoma. 61
33485660 2020
20
Clinical study of serum IGFBP7 in predicting lymphatic metastasis in patients with lung adenocarcinoma. 61
32475626 2020
21
Personalized Medicine and Cervical Screening: Development of Individualized Quantitative Risk Assessments for Cervical Adenocarcinoma and Adenocarcinoma in situ. 61
33260179 2020
22
Urethral Mucinous Adenocarcinoma of the Prostate: An Uncommon and Diagnostically Complex Disease. 61
33045285 2020
23
Discriminating between bronchiolar adenoma, adenocarcinoma in situ and minimally invasive adenocarcinoma of the lung with CT. 61
32482582 2020
24
3D deep learning based classification of pulmonary ground glass opacity nodules with automatic segmentation. 61
33486368 2020
25
Primary Female Urethral Carcinoma: Proposed Staging Modifications Based on Assessment of Female Urethral Histology and Analysis of a Large Series of Female Urethral Carcinomas. 61
32868524 2020
26
MRI of prostatic urethral mucinous urothelial carcinoma: Expanding the differential diagnosis for T2 hyperintense prostatic masses. 61
32574932 2020
27
[Cytological findings in glandular lesions of the uterine cervix]. 61
33113048 2020
28
Aberrant expression of junctional adhesion molecule-A contributes to the malignancy of cervical adenocarcinoma by interaction with poliovirus receptor/CD155. 61
33185939 2020
29
Oncologic and obstetric outcomes after conization for adenocarcinoma in situ or stage IA1 cervical cancer. 61
33199765 2020
30
Lung Adenocarcinoma at CT with 0.25-mm Section Thickness and a 2048 Matrix: High-Spatial-Resolution Imaging for Predicting Invasiveness. 61
32897161 2020
31
Cytology and curetting diagnosis of endocervical adenocarcinoma. 61
32624383 2020
32
Excellent Prognosis of Patients With Invasive Lung Adenocarcinomas During Surgery Misdiagnosed as Atypical Adenomatous Hyperplasia, Adenocarcinoma In Situ, or Minimally Invasive Adenocarcinoma by Frozen Section. 61
33197404 2020
33
Pulmonary Adenocarcinomas of Low Malignant Potential: Proposed Criteria to Expand the Spectrum Beyond Adenocarcinoma In Situ and Minimally Invasive Adenocarcinoma. 61
33177339 2020
34
The value of percentile base on computed tomography histogram in differentiating the invasiveness of adenocarcinoma appearing as pure ground-glass nodules. 61
33157987 2020
35
Cancer-associated fibroblasts, matrix metalloproteinase-9 and lymphatic vessel density are associated with progression from adenocarcinoma in situ to invasive adenocarcinoma of the lung. 61
32934699 2020
36
Genetic Alterations in Preinvasive Lung Synchronous Lesions. 61
32599981 2020
37
HTR3A is correlated with unfavorable histology and promotes proliferation through ERK phosphorylation in lung adenocarcinoma. 61
32736413 2020
38
Expression of PD-L1, PD-L2, and IDO1 on tumor cells and density of CD8-positive tumor-infiltrating lymphocytes in early-stage lung adenocarcinoma according to histological subtype. 61
32405745 2020
39
Do High Rates of Atypical Glandular Cells Correlate With Higher Incidence of Disease in a Large Safety Net Hospital. 61
32569024 2020
40
Assessing Physician Adherence to Guidelines for Cervical Cancer Screening and Management of Abnormal Screening Results. 61
32976292 2020
41
Cervical Stenosis: Previously Unrecognized Cause of False-Negative Human Papillomavirus Tests in Women Developing Cervical Cancer. 61
32881788 2020
42
Diagnostic performance for pulmonary adenocarcinoma on CT: comparison of radiologists with and without three-dimensional convolutional neural network. 61
33011879 2020
43
Hybrid technique of virtual-assisted lung mapping and systemic indocyanine green injection for extended segmentectomy. 61
33108570 2020
44
Computed Tomography-Guided Transfissural Coil Localization of Lung Nodules. 61
31450246 2020
45
A retrospective study of the relationship between the pathologic subtype and lymph node metastasis of lung adenocarcinomas of ≤3 cm diameter. 61
32898994 2020
46
The Evolving Spectrum of Precursor Lesions of Cervical Adenocarcinomas. 61
32482967 2020
47
Superficially Spreading Endocervical Adenocarcinoma in situ with Multifocal Microscopic Involvement of the Endometrial Surface: A Case Report with Emphasis on the Potential for Misdiagnosis Based on Endometrial Curettage Specimens. 61
33564294 2020
48
Is hysterectomy necessary for the treatment of preinvasive stratified mucin producing intraepithelial lesions of the cervix? 61
32448806 2020
49
Assessment of attribution algorithms for resolving CIN3-related HPV genotype prevalence in mixed-genotype biopsy specimens using laser capture microdissection as the reference standard. 61
32736939 2020
50
HPV16/18 prevalence in high-grade cervical lesions in an Australian population offered catch-up HPV vaccination. 61
32736938 2020
Sources

Variations for Adenocarcinoma in Situ

About this section
Sources

Expression for Adenocarcinoma in Situ

About this section
Search GEO for disease gene expression data for Adenocarcinoma in Situ.
Sources

Pathways for Adenocarcinoma in Situ

About this section

Pathways related to Adenocarcinoma in Situ according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Mitotic G1-G1/S phases 65
Show member pathways
 12.17 TOP2A MCM7 MCM2 CDKN2A CDKN1A
2
Cell cycle 36 1
12.06 MCM7 MCM2 CDKN2A CDKN1A
3
DNA Damage 4
11.82 TOP2A MCM7 MCM2 CDKN2A CDKN1A
4
Embryonic and Induced Pluripotent Stem Cell Differentiation Pathways and Lineage-specific Markers 64
11.58 WT1 SOX17 PAX2 CDX2
5
Retinoblastoma (RB) in Cancer 1
11.55 TOP2A MCM7 CDKN1A
6
Platinum drug resistance 36
11.41 TOP2A CDKN2A CDKN1A
7
Bladder cancer 36 1
11.36 KRAS CDKN2A CDKN1A
8
Primary Focal Segmental Glomerulosclerosis FSGS 1
10.79 WT1 PAX2 CLDN1 CDKN1A
Sources

GO Terms for Adenocarcinoma in Situ

About this section

Cellular components related to Adenocarcinoma in Situ according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleolus GO:0005730 9.95 WT1 TOP2A MCM7 MCM2 CDKN2A CDKN1A
2 chromatin GO:0000785 9.87 WT1 SOX17 PAX8 PAX2 MCM7 MCM2
3 nucleus GO:0005634 9.83 WT1 U2AF1 TOP2A SOX17 PAX8 PAX2
4 protein-containing complex GO:0032991 9.63 TOP2A PAX2 CLDN1 CDX2 CDKN2A CDKN1A
5 nucleoplasm GO:0005654 9.4 WT1 U2AF1 TOP2A SOX17 PAX8 PAX2
6 MCM complex GO:0042555 9.37 MCM7 MCM2
7 CMG complex GO:0071162 9.26 MCM7 MCM2

Biological processes related to Adenocarcinoma in Situ according to GeneCards Suite gene sharing:

(show all 27)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription, DNA-templated GO:0045893 10.05 WT1 SOX17 PAX8 PAX2 CDX2 CDKN2A
2 Ras protein signal transduction GO:0007265 9.8 KRAS CDKN2A CDKN1A
3 negative regulation of cell growth GO:0030308 9.76 WT1 SOX17 CDKN2A CDKN1A
4 positive regulation of cell differentiation GO:0045597 9.71 SOX17 INSM1 CDX2
5 branching involved in ureteric bud morphogenesis GO:0001658 9.65 WT1 PAX8 PAX2
6 mesonephros development GO:0001823 9.63 PAX8 PAX2
7 double-strand break repair via break-induced replication GO:0000727 9.63 MCM7 MCM2
8 mesenchymal to epithelial transition GO:0060231 9.62 WT1 PAX2
9 metanephric mesenchyme development GO:0072075 9.61 WT1 PAX2
10 cellular response to gonadotropin stimulus GO:0071371 9.61 WT1 PAX8
11 pre-replicative complex assembly involved in nuclear cell cycle DNA replication GO:0006267 9.6 MCM7 MCM2
12 ureter development GO:0072189 9.59 SOX17 PAX2
13 mesenchymal to epithelial transition involved in metanephros morphogenesis GO:0003337 9.58 PAX8 PAX2
14 regulation of metanephric nephron tubule epithelial cell differentiation GO:0072307 9.57 PAX8 PAX2
15 pronephros development GO:0048793 9.56 PAX8 PAX2
16 metanephric S-shaped body morphogenesis GO:0072284 9.55 WT1 PAX8
17 metanephric nephron tubule formation GO:0072289 9.52 PAX8 PAX2
18 metanephric distal convoluted tubule development GO:0072221 9.51 PAX8 PAX2
19 positive regulation of mesenchymal to epithelial transition involved in metanephros morphogenesis GO:0072108 9.49 PAX8 PAX2
20 positive regulation of metanephric DCT cell differentiation GO:2000594 9.43 PAX8 PAX2
21 negative regulation of apoptotic process involved in metanephric nephron tubule development GO:1900218 9.4 PAX8 PAX2
22 negative regulation of apoptotic process involved in metanephric collecting duct development GO:1900215 9.37 PAX8 PAX2
23 negative regulation of mesenchymal cell apoptotic process involved in metanephros development GO:1900212 9.32 PAX8 PAX2
24 negative regulation of mesenchymal cell apoptotic process involved in metanephric nephron morphogenesis GO:0072305 9.26 PAX8 PAX2
25 G1/S transition of mitotic cell cycle GO:0000082 9.26 MCM7 MCM2 CDKN2A CDKN1A
26 pronephric field specification GO:0039003 9.16 PAX8 PAX2
27 metanephric epithelium development GO:0072207 8.8 WT1 PAX8 PAX2

Molecular functions related to Adenocarcinoma in Situ according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.3 WT1 U2AF1 TOP2A SOX17 PAX8 PAX2
2 transcription regulatory region sequence-specific DNA binding GO:0000976 9.46 WT1 SOX17 PAX8 PAX2
3 DNA-binding transcription factor activity GO:0003700 9.43 WT1 SOX17 PAX8 PAX2 INSM1 CDX2
4 DNA binding GO:0003677 9.32 WT1 TOP2A SOX17 PAX8 PAX2 MCM7
5 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 9.26 CDKN2A CDKN1A
Sources

Sources for Adenocarcinoma in Situ

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....